The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia.
10.19746/j.cnki.issn.1009-2137.2021.02.023
- Author:
Hui-Qin CAO
1
;
Jin-Bao TUO
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Yan'an University, Yan'an 716000, Shaanxi Province, China.
2. Department of Hematology, The Affiliated Hospital of Yan'an University, Yan'an 716000, Shaanxi Province, China,E-mail: 472676438@qq.com.
- Publication Type:Journal Article
- MeSH:
Cell Line, Tumor;
DNA-Binding Proteins/genetics*;
Humans;
Leukemia, Myeloid, Acute/genetics*;
Mutation;
Oncogene Proteins, Fusion/genetics*;
Prognosis;
Repressor Proteins/genetics*;
Transcription Factors/genetics*
- From:
Journal of Experimental Hematology
2021;29(2):450-455
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between acute myeloid leukemia (AML) patients ASXL2, ZBTB7A gene mutations and the prognosis.
METHODS:42 AML Patients treated in our hospital from January 2014 to January 2016 were selected and ASXL2 and ZBTB7A genes of their bone marrow samples were sequenced, the genetic characteristics and prognosis of core-binding factor-AML(CBF-AML) patients with ASXL2 and ZBTB7A mutations were analyzed.
RESULTS:ASXL2 (33.3%) and ZBTB7A (9.5%) mutations were found in t (8; 21) AML patients. Compared with wild-type, patients with ASXL2 mutations showed significantly higher white blood cell count at diagnosis ［(9.49±1.85)×10
CONCLUSION:ASXL2 and ZBTB7A mutations are frequently found in t (8; 21) AML patients. The mutation of ASXL2 and ZBTB7A genes shows no significant effect on the prognosis of AML patients.
